OncoPrecision announced that its development candidate, ONC001, a first-in-class CD64-targeting ADC for monocytic leukemia, will be featured in an oral presentation at the upcoming 67th ASH Annual Meeting. The ADC specifically targets resistant subsets of AML and CMML, utilizing proprietary AI-enhanced discovery to minimize off-target effects. The company is currently advancing ONC001 through IND-enabling studies, highlighting a novel approach to overcoming resistance in blood cancers.